

Patient/carer organisation statement template

Rituximab for the first line maintenance treatment of follicular non-Hodgkin's Lymphoma (FNHL)

Your name: [REDACTED]

Name of your organisation: Leukaemia CARE

Are you (tick all that apply):

- An employee of a patient organisation that represents patients with the condition for which NICE is considering the technology?

Director Campaigning & Patient Advocacy

What do patients and/or carers consider being the advantages and disadvantages of the technology for the condition?

I have had sight of the submission on Rituximab for the first line maintenance treatment of follicular non-Hodgkin's Lymphoma (FNHL) that was prepared and returned to NICE by the Lymphoma Association. It is an accurate and very comprehensive review of the patients' perspective of FNHL and its treatment; and rather than replicate the work that they have very effectively already completed I fully endorse their submission on behalf of Leukaemia CARE.

I trust that this is satisfactory

Kind regards

██████████